GSK to acquire AZ Tika
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline plans to acquire Sweden's leading OTC analgesic treatment, Alvedon, as part of a deal to buy AZ Tika from AstraZeneca for 146 million U.K. pounds ($219 million), the U.K.-based firm announces Nov. 20. AZ Tika's portfolio also includes Minifom, for GI disorders, and the decongestants Nezeril and Nasin, all of which are sold predominantly in Sweden and the Nordic region. The product portfolio's net sales reached about $40.5 million in 2007